Your browser is no longer supported. Please, upgrade your browser.
ALPN Alpine Immune Sciences, Inc. daily Stock Chart
Alpine Immune Sciences, Inc.
Index- P/E- EPS (ttm)-2.55 Insider Own10.19% Shs Outstand13.34M Perf Week4.12%
Market Cap118.06M Forward P/E- EPS next Y-2.25 Insider Trans- Shs Float12.47M Perf Month-8.72%
Income-11.20M PEG- EPS next Q-0.37 Inst Own57.30% Short Float0.26% Perf Quarter-20.34%
Sales1.60M P/S73.79 EPS this Y16.60% Inst Trans1.19% Short Ratio1.85 Perf Half Y-9.60%
Book/sh7.84 P/B1.13 EPS next Y45.70% ROA-19.40% Target Price19.00 Perf Year-24.74%
Cash/sh6.54 P/C1.35 EPS next 5Y- ROE-21.20% 52W Range7.20 - 12.87 Perf YTD-20.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-31.23% Beta-
Dividend %- Quick Ratio32.30 Sales past 5Y- Gross Margin- 52W Low22.86% ATR0.55
Employees29 Current Ratio32.30 Sales Q/Q-82.60% Oper. Margin- RSI (14)43.94 Volatility8.12% 5.93%
OptionableNo Debt/Eq0.06 EPS Q/Q110.50% Profit Margin- Rel Volume1.77 Prev Close8.99
ShortableYes LT Debt/Eq0.05 EarningsMar 26 Payout- Avg Volume17.56K Price8.85
Recom1.00 SMA200.00% SMA50-11.65% SMA200-11.60% Volume31,102 Change-1.56%
Mar-14-18 08:00AM  Alpine Immune Sciences Announces Poster Presentation at the 2018 AACR Annual Meeting Business Wire
Feb-27-18 04:05PM  Alpine Immune Sciences to Present at Cowen 38th Annual Health Care Conference Business Wire -5.75%
Dec-09-17 07:30AM  Alpine Immune Sciences Announces Preclinical Data from ALPN-101 Program Demonstrating Efficacy in Humanized Model of Graft Versus Host Disease Business Wire
Dec-06-17 07:00AM  Alpine Immune Sciences Announces Preclinical Data Showing Novel Immuno-Oncology Costimulatory Molecules Generated from vIgD Platform Fused with Trastuzumab Enhanced Immune Responses Against HER2-Positive Tumor Cells Business Wire
Nov-13-17 04:05PM  Alpine Immune Sciences Reports Corporate Update and Third Quarter 2017 Financial Results Business Wire +5.18%
Nov-10-17 07:00AM  Alpine Immune Sciences Presents Preclinical Data on Novel Immuno-Oncology Molecules at the Society for Immunotherapy of Cancers 32nd Annual Meeting Business Wire
Nov-06-17 07:00AM  Alpine Immune Sciences Presents ALPN-101 Program Data Demonstrating Potent Preclinical Activity in Arthritis and Inflammation Business Wire
Nov-01-17 04:05PM  Alpine Immune Sciences to Present at Two Upcoming Investor Conferences in November Business Wire
Oct-23-17 07:00AM  Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRs Business Wire
Oct-16-17 07:00AM  Alpine Immune Sciences Announces Upcoming Scientific Presentations Business Wire
Sep-20-17 08:00AM  Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting Business Wire
Sep-13-17 04:05PM  Alpine Immune Sciences to Present at Ladenburg Thalmann 2017 Healthcare Conference Business Wire
Aug-09-17 08:43AM  Strength Seen in FibroGen (FGEN): Stock Soars 48.2% Zacks
Alpine Immune Sciences, Inc., a development-stage specialty pharmaceutical company, engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. It is developing ALPN-101, an ICOS/CD28 antagonist program for the treatment of inflammatory diseases. The company is based in Seattle, Washington.